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and veins. Both vasculogenesis and angiogenesis involve
intricate steps of proliferation, migration, and differentia-
tion of endothelial and smooth muscle cells. They are
modulated by multiple growth factors and surrounding
extracellular matrix components, which influence both
blood vessel growth and maturation.5-7 More recently, the
opioid growth factor (OGF), [Met5]-enkephalin, has also
been identified as a modulator of angiogenesis.8
With respect to angiogenesis, the chick chorioallantoic
membrane (CAM) has provided an in vivo model to eval-
uate the effects of modulators on this process.9-13
Furthermore, detailed observations of ultrastructural his-
todifferentiation of vessel formation can be performed on
these preparations.14-17 Several investigators have
attempted to quantify angiogenesis by use of the CAM
model.9-12,18 Strick et al10 examined angiogenic activity by
measuring vessel end point density. Other investigators
attempted to quantify angiogenesis by counting the num-
ber of vessels in a mesh overlay11 or within an implanted
gelatin sponge placed on top of the developing CAM.12
Kurz et al18 have calculated the length and distribution of
Vasculogenesis and angiogenesis are complex
processes.1-4 Vasculogenesis refers to the de novo develop-
ment of blood vessels from mesoderm-derived angioblasts.
These angioblasts differentiate into endothelial cells that
arrange themselves in a tubelike fashion to form a contin-
uous vascular network. Angiogenesis represents the bud-
ding and sprouting of new vessels from preexisting arteries
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Objective: Angiogenesis, the development of new blood vessels, has become an area of increased interest for both scien-
tific and clinical application purposes. Proangiogenic agents, such as vascular endothelial growth factor (VEGF) and
naltrexone, have been shown to effectively induce new blood vessel growth. Other growth factors, such as the endoge-
nous opioid growth factor (OGF; [Met5]-enkephalin) and retinoic acid, are inhibitors of angiogenesis. The differential
effects on veins and arteries, however, by any vascular growth factor, have not previously been investigated. 
Methods: The chick chorioallantoic membrane (CAM) assay was used for the in vivo quantitation of angiogenesis. After
3 days of incubation, fertilized chick embryos were explanted, and a 3.2-mm methylcellulose disk containing either the
known angiogenic stimulators VEGF (0.2 µg, 1.0 µg) or naltrexone (0.1 µg, 5.0 µg), or the angiogenic inhibitors OGF
(1.0 µg, 5.0 µg) or retinoic acid (1.0 µg) was placed onto the CAM surface. An equal volume of distilled water served
as a control. After 2 days of growth, the CAM arteries and veins were identified, and images were obtained with a dig-
ital camera. Quantitative analysis of angiogenesis was performed on a 100-mm2 area surrounding the applied disk, and
the number and length of the veins and arteries were measured.
Results: The angiogenic stimulators VEGF and naltrexone markedly increased both the total number and length of all
blood vessels as compared with control values. The mean length of blood vessels decreased, suggesting the induction
of new vessel growth. VEGF and naltrexone proportionately increased vein and arterial angiogenesis, maintaining
artery/vein ratios for vessel number and length that were unchanged compared with controls. The angiogenic
inhibitors, OGF and retinoic acid, notably decreased the total number and length of blood vessels in the CAM prepa-
rations. However, these compounds had a disproportionately greater inhibitory effect on arterial angiogenesis as
reflected in decreased artery/vein ratios for vessel number and length. 
Conclusions: The angiogenic stimulators VEGF and naltrexone induce development of veins and arteries in a propor-
tional manner. In contrast, the angiogenic inhibitors OGF and retinoic acid demonstrated a greater inhibitory effect
on arterial as compared with venous angiogenesis. Such differential effects on angiogenesis may be important in both
defining mechanisms of action and designing therapeutic interventions. (J Vasc Surg 2002;35:532-8.)
proliferating precapillary blood vessel formation. Recently,
a method to directly quantify the total number and length
of blood vessels in the CAM within a defined area sur-
rounding applied disks containing angiogenic mediators
has been reported.8,13
Arteries and veins are functionally and morphologically
different. Furthermore, it has recently been shown that
arterial and venous endothelial cells are molecularly distinct
beginning at the earliest stages of angiogenesis.19-21
Previous studies on angiogenesis, however, have not exam-
ined the potential differential effects of angiogenic stimula-
tors and inhibitors on the development of arteries and
veins. Thus there may be different therapeutic implications
for angiogenic modulators on arterial and venous diseases.
In this study we have addressed the influence of vas-
cular growth factors on arterial and venous angiogenesis
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with the CAM model. The results of this investigation
document for the first time differential effects by vascular
growth stimulators, such as vascular endothelial growth
factor (VEGF) and naltrexone, and the angiogenic
inhibitors OGF ([Met5]-enkephalin) and retinoic acid, on
arterial and venous growth and development. 
MATERIAL AND METHODS
Chorioallantoic model. The CAM model used in
these studies has been described earlier.8,13 In brief, fertil-
ized white broiler chicken eggs were purchased from a
local hatchery and maintained at room temperature for 1
day. The eggs were incubated at 37° C for 3 days and then
cracked, and the embryos were explanted into spherical
plastic 100-mm × 25-mm weigh boats (VWR Scientific,
Bridgeport, NJ). The specimens were covered with a ster-
Fig 1. Digitized computer images of CAMs. White circles represent location of applied disks. Artery is ori-
ented vertically with blood flowing antegrade from bottom to top of each illustration; veins have blood
flowing in opposite direction. Arterial branches are indicated by arrow whereas venous branches are shown
by arrowhead. A, Control specimen with venous branches intercalating between arterioles. B, Specimen
exposed to VEGF shows increased vascularity. C, Treatment with opioid growth factor decreased number
of arteries and veins in region of applied disk. D, Application of retinoic acid diminished growth of arter-
ies and veins. All photographs were performed at same magnification (bar = 2 mm), with unselected vari-
ability in vessel size.
ile plastic lid and allowed to grow an additional 72 hours
in a humidified incubator until the CAM diameter was at
least 10 mm in size.
Drug delivery. Methylcellulose disks containing
methylcellulose 4.5 mol/L were prepared for drug deliv-
ery as previously described.8,13 VEGF (0.2 µg, n = 10;
1.0 µg, n = 14), naltrexone (0.1 µg, n = 10; 5.0 µg, n =
11), OGF (1 µg, n = 9; 5.0 µg, n = 9), and retinoic acid
(1.0 µg, n = 9) were each mixed in distilled water 10 µL.
Dosages were selected on the basis of our prior work8,13
and to evaluate possible differential dose responses.
Controls (n = 30, total) were performed with each series
of angioactive agents and contained an equal volume of
distilled water. Each of these solutions was combined
with 10 µL of the methylcellulose preparation and placed
on the tips of sterile 3.2-mm diameter polytetrafluo-
roethylene-coated rods and allowed to dry at room tem-
perature under a vacuum hood. The dried disks were
placed onto the outer third surface of the CAM, and the
specimens were returned to the humidified incubator for
an additional 48 hours of growth before undergoing
quantitative image analysis. Only one disk was placed on
each CAM.
Reagent-grade chemicals were used: VEGF (>97%
pure by SDS-PAGE), naltrexone (>99% pure by TLC),
transretinoic acid (>99.8% pure by high-pressure liquid
chromatography), all from Sigma-Aldrich (St. Louis, Mo)
and OGF (99% pure by reverse phase–high-pressure liquid
chromatography) from Multiple Peptide Systems (San
Diego, Calif).
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Image analysis. The location of the disk on the CAM
was visually identified and marked with a surgical marker.
The veins and arteries were identified under a dissecting
microscope (Olympus SZX12; Olympus, Tokyo, Japan)
on the basis of the presence of vessel pulsation, color, and
direction of blood flow within the vessels. For consistency,
the main artery nearest the disk was oriented vertically
with flow originating inferiorly (Fig 1). A white 10%
intralipid solution was injected beneath the CAM to
obscure the underlying embryo and yolk vessels and to
enhance visibility of the overlying superficial CAM vessels.
The images were captured with a three-chip digital camera
(Sony DKC-5000; Sony, Tokyo, Japan) and exported to a
personal computer. Calibration was achieved by imaging a
ruler placed adjacent to the embryo preparation.
From this digitized image, an overlying mask was cre-
ated, and all blood vessels within a 100-mm2 area sur-
rounding the applied disk were traced and analyzed in a
random but unblinded manner by two different individu-
als (Optimas 6.2; Mediacybernetics, Bothell, Wash). The
total number and length of the veins and arteries were
counted and measured once for each experiment.
Individual vessel lengths were added to obtain total blood
vessel lengths. In six experiments, both readers performed
the measurements twice separately and in a blinded man-
ner. Their results were then compared for interobserver
and intraobserver variability. There were no significant dif-
ferences for either the number or length of vessels mea-
sured, between observers or by the same reader with
measurements done on different days. The interobserver
variability was found to be 3% for the number of vessels
and 9% for vessel length, whereas the intraobserver vari-
ability was 7% and 16%, respectively (unpublished data).
Statistics. All values are reported as mean ± standard
error of the mean. Statistical analysis was performed by use
of the Sigma Stat 2.0 statistical software package (Jandel,
San Rafael, Calif). Student’s t testing was used for data
comparisons within groups that had at least five simulta-
neous controls performed. When fewer controls were
available within each group, comparisons were made with
the combined control results from all experiments, by use
of one-way analysis of variance (ANOVA). Correction for
multiple comparisons was made by use of Dunnett’s test-
ing for post hoc analysis or Kruskal-Wallis ANOVA on
ranks when the data were not normally distributed. A P
value < .05 was considered statistically significant.
RESULTS
In comparison to controls, CAM preparations exposed
to 1.0 µg of VEGF exhibited significant increases in the
total number and length of all blood vessels by 95% and
25%, respectively (Figs 1, B, 2, and 3). This effect reflected
an increased number of smaller vessels, because the mean
blood vessel length of the 1.0 µg VEGF group decreased
by 38% as compared with control values (Fig 4). A lower
dosage of VEGF (0.2 µg) did not alter either the total
length or mean length of blood vessels from control val-
ues, but the number of vessels was decreased by 20% (Figs
Fig 2. Total number of blood vessels in region around applied
disks. Number of blood vessels was increased after exposure to
VEGF (1.0 µg) or naltrexone (NTX, 5.0 µg) but was decreased
in preparations treated with OGF (1.0 µg, 5.0 µg) and retinoic
acid (RA, 1.0 µg) compared with controls. Significantly different
from controls at *P < .05; §P < .005; and #P < .0001.
2 to 4). The opioid antagonist naltrexone, at a dose of 5.0
µg, significantly increased the total vessel number and
length by 59% and 20%, respectively, compared with the
control preparations, whereas mean vessel length
decreased by 31% (Figs 2 to 4). In the group treated with
1.0 µg of naltrexone, vessel number, length, and mean
vessel length were comparable with control values.
The specific effects of the proangiogenic modulators,
VEGF and naltrexone, on veins and arteries were exam-
ined. In control preparations, there were twice as many
arteries as veins, with a resulting artery/vein ratio of 2.0 ±
0.1, whereas total arterial length was also greater than
venous length with a ratio of 1.6 ± 0.0 (Fig 1, A, Table).
Treatment with 1.0 µg of VEGF increased new blood ves-
sel growth with venous and arterial angiogenesis affected
in a similar manner. The number of arteries and veins
increased by 108% and 74%, respectively, whereas the
lengths of arteries and veins increased by 26% and 23%,
respectively, compared with control preparations. The
resultant artery/vein ratios with respect to vessel number
and length in the 1.0 µg VEGF group did not differ from
those of control specimens (Table). The mean length of
the arteries and veins also decreased proportionately, by
42% and 28%, respectively, from control values, after appli-
cation of 1.0 µg VEGF. The addition of 0.2 µg of VEGF
induced a 30% decrease in the number of arteries and a
15% decrease in arterial length from control levels. There
were no associated changes in venous growth, leading to a
decrease in the artery/vein ratios as compared with con-
trol specimens (Table). Exposure to naltrexone at 5.0 µg
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resulted in a proportional increase in the number of arter-
ies and veins, by 71% and 41%, respectively, from control
values and an increase in the lengths of arteries and veins
by 27% and 11%, respectively. No change in the
artery/vein ratios with respect to vessel number was
observed compared with control preparations (Table).
Specimens treated with lower doses of naltrexone 1 µg did
not differ in arterial and venous parameters from the con-
trol group.
In examining the angiogenic inhibitor OGF, at a dose
of 5 µg, decreases in the total number and length of all
blood vessels by 31% and 19%, respectively, as compared
with control values, were recorded (Figs 1, C, 2, and 3).
The angiogenic inhibitor retinoic acid significantly
decreased the total number and length of blood vessels by
48% and 36%, respectively, from control levels (Figs 1, D,
2, and 3). Mean blood vessel length of the retinoic acid
and OGF groups were both increased by 15% from con-
trol values, indicating the presence of fewer shorter vessels
(Fig 4).
In general, the angiogenic inhibitors OGF and
retinoic acid appeared to have a greater effect on arterial
as compared with venous angiogenesis (Table). OGF at 5
µg decreased the total number and length of arteries from
control values by 34% and 22%, respectively, whereas the
total number and length of veins were reduced 23% and
14%, respectively. These changes in the OGF 5 µg were
specifically reflected in a reduction in the artery/vein ratio
for the number of vessels (1.6 ± 0.1) and the length of ves-
sels (1.3 ± 0.1), suggesting a greater inhibitory effect on
Fig 3. Total blood vessel length in region around applied disks in
CAMs exposed to VEGF (1.0 µg) or naltrexone (NTX, 5.0 µg)
was significantly increased whereas in preparations treated with
OGF (1.0 µg, 5.0 µg) or retinoic acid (RA, 1.0 µg), blood vessel
length decreased. Significantly different from controls at *P < .05;
§P < .005; and #P < .0001.
Fig 4. Mean blood vessel length in 100 mm2 region around
disks. VEGF (1.0 µg) and naltrexone (NTX, 5.0 µg) groups
demonstrated significant decrease compared with control group,
whereas OGF (1.0 µg, 5.0 µg) and retinoic acid (RA, 1.0 µg)
increased mean blood vessel length. Significantly different from
controls at *P < .05 and #P < .0001.
arteries as compared with veins (Table). The specimens
treated with the 1-µg dose of OGF demonstrated a simi-
lar pattern of angiogenic inhibition to that observed with
5 µg OGF (Table). Exposure to retinoic acid also had a
disproportional effect on arterial development. The num-
ber and lengths of arteries decreased by 50% and 39%, and
the number and lengths of veins by 43% and 31%, respec-
tively, compared with the control group. Treatment with
retinoic acid significantly decreased associated vessel num-
ber and length artery/vein ratios in comparison to con-
trols (Table). 
DISCUSSION
The results of this study show that VEGF and naltrex-
one have a dose-dependent stimulatory influence on
angiogenesis by use of the CAM model. In both cases, this
was associated with a decrease in the mean length of both
the veins and arteries, suggesting that much of this growth
was due to the outgrowth of smaller branch vessels rather
than merely the continued growth of arteries and veins
that were already present. Indeed, a VEGF adenoviral vec-
tor was found to stimulate vessel sprouting22 and
increased branching patterns were seen in transgenic mice
with induced angiogenesis through the overexpression of
fibroblast growth factor.23 Moreover, our data reveal that
OGF and retinoic acid depress blood vessel growth. In
contrast to VEGF and naltrexone, exposure to OGF or
retinoic acid significantly decreased the number and
length of blood vessels, with a resultant increase in the
mean length of remaining vessels. The results of these
experiments are consistent with those reported earlier on
proangiogenic (VEGF, naltrexone) and antiangiogenic
(OGF, retinoic acid) substances8 and show that the model
system used herein was comparable to that published in
previous investigations.
The question addressed in this study was what influ-
ence is exerted by angiogenic factors on arteries and veins?
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Our data, for the first time, indicate a differential modula-
tion of venous and arterial angiogenesis with variable
effects shown by angiogenic and antiangiogenic agents.
Stimulatory agents of angiogenesis, VEGF and naltrexone,
induced venous and arterial angiogenesis proportionately,
maintaining the same 2:1 relative ratio of number of arter-
ies to veins as in control preparations. In a similar manner,
when the total length of arteries and veins was analyzed,
increased angiogenesis by VEGF and naltrexone resulted
in no significant change from the control ratio of 1.6:1. In
contrast, antiangiogenic factors (OGF, retinoic acid)
decreased arterial and venous angiogenesis but did so in a
disproportionate fashion so that arteries were altered to a
greater magnitude than veins. This was suggested by the
decrease in the artery/vein ratios to 1.5:1 for the number
and 1.3:1 for the length of vessels seen in these prepara-
tions. These results, on vessels functionally analogous to
human pulmonary arteries and veins, would suggest that
arterial development is more sensitive than veins to repres-
sive growth factors, although the reason(s) for this are
presently unclear. Greater arterial sensitivity, or arterial
selectivity of these particular agents, is also suggested by
the effects seen on arteries by lower doses of VEGF and
OGF, when veins were not yet affected. Within the con-
fines of the restricted number of agents and dosages used,
we can propose that angiogenic modulators in general,
and proangiogenic agents and antiangiogenic factors in
particular, act differently on veins and arteries, but further
studies are required to clarify this hypothesis.
Although relatively little is known of the process of
differentiation of the vascular system, and how arteries and
veins acquire their distinct structure and function, there is
both an anatomic and physiological basis to explain differ-
ences in angiogenic responsivity. Recently, a molecular dis-
tinction between arterial and venous endothelial cells has
been demonstrated suggesting that vessel morphogenesis
is partly genetically predetermined. Wang et al19 found
Differential effects of angiogenic mediators on CAM preparations
Number of vessels Total vessel length (mm)
Disk Artery Vein Artery/vein ratio Artery Vein Artery/vein ratio
Control (n = 30) 119 ± 5 69 ± 2 2.0 ± 0.1 137 ± 3 95 ± 3 1.6 ± 0.0
VEGF
0.2 µg (n = 10) 83 ± 5* 75 ± 11 1.3 ± 0.1* 117 ± 3* 109 ± 14 1.2 ± 0.1*
1.0 µg (n = 14) 248 ± 13† 120 ± 7† 2.2 ± .02 173 ± 8† 117 ± 5† 1.5 ± 0.2
Naltrexone
0.1 µg (n = 10) 80 ± 6 83 ± 4 1.0 ± 0.1 112 ± 6 118 ± 6 1.0 ± 0.1
5.0 µg (n = 11) 203 ± 7* 97 ± 4* 2.1 ± 0.1 174 ± 4* 105 ± 2 1.7 ± 0.0
OGF
1.0 µg (n = 9) 53 ± 5† 56 ± 8 1.1 ± 0.2 84 ± 5‡ 81 ± 11 1.2 ± 0.2
5.0 µg (n = 9) 79 ± 4* 51 ± 2* 1.6 ± 0.1* 107 ± 4* 82 ± 3 1.3 ± 0.1
Retinoic acid (n = 9) 60 ± 5* 39 ± 3* 1.5 ± 0.1* 83 ± 5* 66 ± 4* 1.3 ± 0.1*
Data represent mean ± SEM.
*Significantly different from group controls at P < .05 by use of ANOVA with post hoc testing.
†Significantly different from controls, P < .0001, by use of a two-tailed t test.
‡Significantly different from controls, P < .005, by use of a two-tailed t test.
that ephrin-B2, a transmembrane ligand, was expressed on
arterial but not venous endothelial cells from the earliest
stages of angiogenesis. On the other hand, EphB4, a
receptor for ephrin-B2, was observed only on venous
endothelial cells. Moreover, signaling between arteries and
veins appears essential for vessel morphogenesis and
remodeling. Disruption of the ephrin-B2 ligand gene
caused not only a defect in EphB4 receptor, thus blocking
venous angiogenesis, but also a concomitant defect in the
arteries.19,21 Therefore a reciprocal interaction between
these two classes of vessels appears essential for angiogen-
esis and is codependently related at the molecular level.
Adams et al20 demonstrated that ephrin-B2 and EphB4
have a functional and physiologically relevant interaction,
which is not restricted to the arterial-venous boundary but
may occur at the endothelial-mesenchymal contact zones.
Others have shown a temporal relationship between
changes in extracellular matrix composition and blood ves-
sel morphogenesis. Murphy et al6 suggested that the
sequential production of basal lamina, collagen(s), and
glycosaminoglycans by the developing vessel epithelia may
be critical to their final differentiation. The differentiation
of arteries and veins in the chick chorioallantoic mem-
brane correlates with the selective disappearance of
hyaluronic acid and the accumulation of sulfated gly-
cosaminoglycans in the walls of these vessels.7 Differences
between veins and arteries are also present in other com-
ponents of the vessel wall. Moessler et al24 have demon-
strated differential expression of smooth muscle-specific
protein SM 22 in arteries but not in veins. Superimposed
on such anatomic differences, the arrangement of arteries
and veins and their histodifferentiation may be influenced
by the amount and direction of regional blood flow and
pressure.17,25,26
The angiogenic agents examined in these experiments
are believed to act principally at the level of the endothe-
lial cell. VEGF and its endothelial cell receptors have been
studied most extensively. Mice with homozygous disrup-
tions of VEGF receptor genes die at mid gestation from
vascular structural and functional defects.27 A defect in the
gene for VEGF receptor VEGFR-2 (flk-1) in mutant mice
interfered with the differentiation of vascular endothelial
cells, resulting in complete absence of organized blood
vessels and embryonic death within 10 days of gestation.
Disruption of another receptor gene, VEGFR-1 (flt-1),
although not essential for endothelial cell differentiation,
resulted in abnormal and disorganized vascular channels
and early embryonic death.28 It has been established that
the activities of OGF are receptor mediated.29 Previously,8
we had demonstrated that both OGF and its receptor
were present in the endothelial cells lining the lumen of
developing vessels, but it is presently unknown whether
there is a differential expression of opioid receptor
between arteries and veins. Although our results suggest
that arterial and venous endothelial cells may respond dif-
ferently to positive and negative angiogenic signals, and
such expression may be dose dependent, the underlying
regulating mechanisms remain to be defined. We suspect
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that there are multiple different pathways of activators and
inhibitors of angiogenesis with a complex relationship.
There appears to be codependency and reciprocal com-
munication between arteries and veins required for vessel
growth and morphogenesis. This developmental interac-
tion may be disrupted to a greater degree with the appli-
cation of antiangiogenic agents. Retinoic acid and OGF
both showed greater inhibitory arterial specificity and sen-
sitivity, although they are not known to share a common
pathway of action. Restoration of vessel growth and nor-
malization of artery/vein ratios with the OGF competitive
receptor antagonist naltrexone suggest that the effect of
OGF is receptor dependent, although it is not known to
cross-react with any VEGF receptors. 
These results are important for potential future clini-
cal implementation. Determination of these underlying
mechanisms and the vessel specificity of angiogenic mod-
ulators may lead to new approaches to therapeutic inter-
ventions directed selectively at arteries or veins.
Angiogenic therapy may be used not only to assist in the
development of additional collateral arterial vessels for
patients with peripheral vascular30 or cardiac insuffi-
ciency31 but also to inhibit benign or malignant tumor
growth,32 abnormal venous growth, and congenital vascu-
lar malformations.33
Special thanks are extended to Sprague W. Hazard,
BS, for technical assistance in the performance of these
experiments. 
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